Cell transfer‐based immunotherapies in cancer: A review

Gorabi, Armita Mahdavi; Hajighasemi, Saeideh; Sathyapalan, Thozhukat; Sahebkar, Amirhossein

doi:10.1002/iub.2180

Cited by 13 publications

(9 citation statements)

References 106 publications

(233 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One of the main advantages of this cell type is that they are found in high levels in blood under normal conditions, and in addition, their number can be incremented further upon in vivo treatment with G-CSF and GM-CSF cytokines ( 111 , 112 ). Another feature that makes them unique is that neutrophils do not need ex vivo culturing and expansion for a later infusion into the patient, compared to most other immune cells used therapeutically, such as T cells, NK cells or DCs ( 113 ). Siders et al showed that increasing the number of circulating neutrophils by a mere injection of G-CSF turned them into excellent cytotoxic cells that were able to kill alemtuzumab-opsonized cells in a xenograft model of a CD52 + tumor ( 114 ).…”

Section: Role Of Neutrophils In Tumor Eliminationmentioning

confidence: 99%

Plasticity in Pro- and Anti-tumor Activity of Neutrophils: Shifting the Balance

et al. 2020

View full text Add to dashboard Cite

Over the last decades, cancer immunotherapies such as checkpoint blockade and adoptive T cell transfer have been a game changer in many aspects and have improved the treatment for various malignancies considerably. Despite the clinical success of harnessing the adaptive immunity to combat the tumor, the benefits of immunotherapy are still limited to a subset of patients and cancer types. In recent years, neutrophils, the most abundant circulating leukocytes, have emerged as promising targets for anti-cancer therapies. Traditionally regarded as the first line of defense against infections, neutrophils are increasingly recognized as critical players during cancer progression. Evidence shows the functional plasticity of neutrophils in the tumor microenvironment, allowing neutrophils to exert either pro-tumor or anti-tumor effects. This review describes the tumor-promoting roles of neutrophils, focusing on their myeloid-derived suppressor cell activity, as well as their role in tumor elimination, exerted mainly via antibody-dependent cellular cytotoxicity. We will discuss potential approaches to therapeutically target neutrophils in cancer. These include strategies in humans to either silence the pro-tumor activity of neutrophils, or to activate or enhance their anti-tumor functions. Redirecting neutrophils seems a promising approach to harness innate immunity to improve treatment for cancer patients.

show abstract

Section: Role Of Neutrophils In Tumor Eliminationmentioning

confidence: 99%

Plasticity in Pro- and Anti-tumor Activity of Neutrophils: Shifting the Balance

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Exciting achievements and outcomes were obtained in treating hematologic malignancies with CAR-T cells 4 , 5 , 8 and advanced or metastatic solid tumors with antibodies to cytotoxic T lymphocyte antigen-4 (CTLA-4 and programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1). 9 , 10 , 11 , 12 Additionally, adaptive cell therapy (ACT) has been widely accepted and applied in clinics with some promising results, 13 although it faces challenges of specificity and efficacy. 5 , 6 , 14 As such, researchers were looking for more specific immune cells for ACT.…”

Section: Introductionmentioning

confidence: 99%

Prognostic and therapeutic TILs of cervical cancer—Current advances and future perspectives

Tang

Zhang²,

Chen³

et al. 2021

Molecular Therapy - Oncolytics

View full text Add to dashboard Cite

Cervical cancer is a top lethal cancer for women worldwide. Although screening and vaccination programs are available in many countries, resulting in the decline of new cases, this is not true for developing countries where there are many new cases and related deaths. Cancer immunotherapy through adaptive cell therapy (ACT) has been applied in clinics, but now much attention is focused on autogenic tumor-infiltrating lymphocyte (TIL)-based therapy, which has shown more specificity and better ability to inhibit tumor growth. Data from melanoma and cervical cancers confirm that tumor-specific T cells in TILs can be expanded for more specific and effective ACT. Moreover, TILs are derived from individual patients and are ready to home back to kill tumor cells after patient infusion, aligning well with personalized and precision medicine. In addition to therapy, TIL cell types and numbers are good indicators of host immune response to the tumor, and thus they have significant values in prognosis. Because of the special relationship with human papillomavirus (HPV) infection, cervical cancer has some specialties in TIL-based prognosis and therapy. In this review, we summarize the recent advances in the prognostic significance of TILs and TIL-based therapy for cervical cancer and discuss related perspectives.

show abstract

“…Such modification has raised the acceptation levels of immune therapies. However, efficacy in delivering the antitumor immune response with immune stimulation is challenging, as it requires proper monitoring with minimum antigen loss and trafficking in a biological system [67]. Cancer vaccines are another form of cancer immunotherapies where tumor specific antigens (polypeptides, DNA and RNA) are exploited for building immunogenic response, which can trigger antitumor expressions, thereby, generating antitumor immunity with additional support from adjuvant molecules for improved tumor killing response.…”

Section: Cancer Immunotherapies Present Status and Concernsmentioning

confidence: 99%

Nano-immunotherapeutics: targeting approach as strategic regulation at tumor microenvironment for cancer treatment

Singh

Yadav

Niveria

et al. 2022

Exploration of Medicine

View full text Add to dashboard Cite

Cancer is the leading cause of mortality worldwide, which necessitates our consideration related to novel treatment approach. Tumor cells at the tumor microenvironment (TME), regulate a plethora of key mechanistic signaling pathways that obstruct antitumor immune responses by immune suppression, immune resistance or acquired immune tolerance. The present therapeutic regimes are provided independently or in combination, or as immunotherapies for cancer immune targeting. Immunotherapy has altered the arena of oncology and patient care. By using the host immune system, the immunostimulatory molecules can exert a robust, personalized response against the patient’s own tumors. Alternatively, tumors may exploit these strategies to escape immune recognition, and accordingly, such mechanisms represent chances for immunotherapy intervention. Nonetheless, despite promising outcomes from immunotherapies in recurrent and metastatic cancers, immune-therapeutics in clinics has been limited owing to unpredictability in the produced immune response and reported instances of immune-related adverse effects. The unrealized potential of immunotherapies in cancer management maybe due to the obstacles such as heterogeneous nature, multiple targets, patients’ immune response, specificity for cancer or variability in response generation in toxicity levels, delivery and cost related to therapeutics etc. Further revolutionary trends related to immunotherapies are noticeable with slower progress for cancer management. Recent advances in nanomedicine strategize to ameliorate the lacuna of immunotherapy as it relies on the inherent biophysical characteristics of nanocarriers: size, shape, surface charge and multifunctionality and exploiting them as first line therapy for delivery of biomolecules, single checkpoint inhibitors and for imaging of TME. Therefore, nano-assisted immunotherapies can boost the immunotherapeutic approach, overcoming factors that are with imminent potential risks related to it, thereby significantly improving the survival rate associated with it in cancer patients. Nanotechnology is anticipated to overcome the confines of existing cancer immunotherapy and to successfully combine various cancer treatment modes.

show abstract

Cell transfer‐based immunotherapies in cancer: A review

Cited by 13 publications

References 106 publications

Plasticity in Pro- and Anti-tumor Activity of Neutrophils: Shifting the Balance

Plasticity in Pro- and Anti-tumor Activity of Neutrophils: Shifting the Balance

Prognostic and therapeutic TILs of cervical cancer—Current advances and future perspectives

Nano-immunotherapeutics: targeting approach as strategic regulation at tumor microenvironment for cancer treatment

Contact Info

Product

Resources

About